240 related articles for article (PubMed ID: 33399817)
1. Levoketoconazole, the 2S,4R Enantiomer of Ketoconazole, a New Steroidogenesis Inhibitor for Cushing's Syndrome Treatment.
Creemers SG; Feelders RA; de Jong FH; Franssen GJH; de Rijke YB; van Koetsveld PM; Hofland LJ
J Clin Endocrinol Metab; 2021 Mar; 106(4):e1618-e1630. PubMed ID: 33399817
[TBL] [Abstract][Full Text] [Related]
2. Levoketoconazole: a novel treatment for endogenous Cushing's syndrome.
Fleseriu M; Auchus RJ; Pivonello R; Salvatori R; Zacharieva S; Biller BMK
Expert Rev Endocrinol Metab; 2021 Jul; 16(4):159-174. PubMed ID: 34380370
[No Abstract] [Full Text] [Related]
3. Therapy of Cushing's syndrome with steroid biosynthesis inhibitors.
Engelhardt D; Weber MM
J Steroid Biochem Mol Biol; 1994 Jun; 49(4-6):261-7. PubMed ID: 8043488
[TBL] [Abstract][Full Text] [Related]
4. Osilodrostat Is a Potential Novel Steroidogenesis Inhibitor for the Treatment of Cushing Syndrome: An In Vitro Study.
Creemers SG; Feelders RA; de Jong FH; Franssen GJH; de Rijke YB; van Koetsveld PM; Hofland LJ
J Clin Endocrinol Metab; 2019 Aug; 104(8):3437-3449. PubMed ID: 31127821
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing's syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial.
Fleseriu M; Pivonello R; Elenkova A; Salvatori R; Auchus RJ; Feelders RA; Geer EB; Greenman Y; Witek P; Cohen F; Biller BMK
Lancet Diabetes Endocrinol; 2019 Nov; 7(11):855-865. PubMed ID: 31542384
[TBL] [Abstract][Full Text] [Related]
6. Corticotropin-dependent Cushing's syndrome in older people: presentation of five cases and therapeutical use of ketoconazole.
Berwaerts JJ; Verhelst JA; Verhaert GC; Verhaegen AA; Abs RE
J Am Geriatr Soc; 1998 Jul; 46(7):880-4. PubMed ID: 9670876
[TBL] [Abstract][Full Text] [Related]
7. Cushing's disease: adrenal steroidogenesis inhibitors.
Pivonello R; Simeoli C; Di Paola N; Colao A
Pituitary; 2022 Oct; 25(5):726-732. PubMed ID: 36036308
[TBL] [Abstract][Full Text] [Related]
8. Updates on the role of adrenal steroidogenesis inhibitors in Cushing's syndrome: a focus on novel therapies.
Fleseriu M; Castinetti F
Pituitary; 2016 Dec; 19(6):643-653. PubMed ID: 27600150
[TBL] [Abstract][Full Text] [Related]
9. Different therapeutic efficacy of ketoconazole in patients with Cushing's syndrome.
Engelhardt D; Jacob K; Doerr HG
Klin Wochenschr; 1989 Feb; 67(4):241-7. PubMed ID: 2538676
[TBL] [Abstract][Full Text] [Related]
10. Primary adrenocortical micronodular adenomatosis causing Cushing's syndrome. Effects of ketoconazole on steroid production and in vitro performance of adrenal cells.
Oelkers W; Bähr V; Hensen J; Pickartz H
Acta Endocrinol (Copenh); 1986 Nov; 113(3):370-7. PubMed ID: 3538739
[TBL] [Abstract][Full Text] [Related]
11. Classic and recent etiologies of Cushing's syndrome: diagnosis and therapy.
Beauregard C; Dickstein G; Lacroix A
Treat Endocrinol; 2002; 1(2):79-94. PubMed ID: 15765624
[TBL] [Abstract][Full Text] [Related]
12. Response of pituitary-adrenal axis to corticotrophin releasing hormone in patients with Cushing's disease before and after ketoconazole treatment.
Boscaro M; Sonino N; Rampazzo A; Mantero F
Clin Endocrinol (Oxf); 1987 Oct; 27(4):461-7. PubMed ID: 2830063
[TBL] [Abstract][Full Text] [Related]
13. Levoketoconazole in the treatment of patients with endogenous Cushing's syndrome: a double-blind, placebo-controlled, randomized withdrawal study (LOGICS).
Pivonello R; Zacharieva S; Elenkova A; Tóth M; Shimon I; Stigliano A; Badiu C; Brue T; Georgescu CE; Tsagarakis S; Cohen F; Fleseriu M
Pituitary; 2022 Dec; 25(6):911-926. PubMed ID: 36085339
[TBL] [Abstract][Full Text] [Related]
14. Ketoconazole treatment in Cushing's disease. Effect on the circadian profile of plasma ACTH and cortisol.
Terzolo M; Panarelli M; Piovesan A; Torta M; Paccotti P; Angeli A
J Endocrinol Invest; 1988 Nov; 11(10):717-21. PubMed ID: 2852693
[TBL] [Abstract][Full Text] [Related]
15. ACTH response to corticotropin releasing hormone in Cushing's disease before and after ketoconazole: in vivo and in vitro studies.
Boscaro M; Sonino N; Rampazzo A; Menegus AM; Mantero F
Horm Metab Res Suppl; 1987; 16():60-2. PubMed ID: 2832292
[TBL] [Abstract][Full Text] [Related]
16. Adrenocorticotrophic hormone (ACTH) responsiveness to ghrelin increases after 6 months of ketoconazole use in patients with Cushing's disease: comparison with GH-releasing peptide-6 (GHRP-6).
Correa-Silva SR; Nascif SO; Molica P; Sá LB; Vieira JG; Lengyel AM
Clin Endocrinol (Oxf); 2010 Jan; 72(1):70-5. PubMed ID: 19453623
[TBL] [Abstract][Full Text] [Related]
17. Approach to the Patient Treated with Steroidogenesis Inhibitors.
Castinetti F; Nieman LK; Reincke M; Newell-Price J
J Clin Endocrinol Metab; 2021 Jun; 106(7):2114-2123. PubMed ID: 33675650
[TBL] [Abstract][Full Text] [Related]
18. Fluconazole inhibits human adrenocortical steroidogenesis in vitro.
van der Pas R; Hofland LJ; Hofland J; Taylor AE; Arlt W; Steenbergen J; van Koetsveld PM; de Herder WW; de Jong FH; Feelders RA
J Endocrinol; 2012 Dec; 215(3):403-12. PubMed ID: 23038793
[TBL] [Abstract][Full Text] [Related]
19. Use of ketoconazole in the treatment of Cushing's syndrome.
Loli P; Berselli ME; Tagliaferri M
J Clin Endocrinol Metab; 1986 Dec; 63(6):1365-71. PubMed ID: 3023421
[TBL] [Abstract][Full Text] [Related]
20. Drugs in the medical treatment of Cushing's syndrome.
Schteingart DE
Expert Opin Emerg Drugs; 2009 Dec; 14(4):661-71. PubMed ID: 19939210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
